The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 13 of the 31 sources its claims cite were checked for support.
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Open accessAbstract
BACKGROUND: G protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells. METHODS: In a phase 1 study, we evaluated talquetamab administered intravenously weekly or every other week (in doses from 0.5 to 180 μg per kilogram of body weight) or subcutaneously weekly, every other week, or monthly (5 to 1600 μg per kilogram) in patients who had heavily pretreated relapsed or refractory multiple myeloma that had progressed with established therapies (a median of six previous lines of therapy) or who could not receive these therapies without unacceptable side effects. The primary end points - the frequency and type of dose-limiting toxic effects (study part 1 only), adverse events, and laboratory abnormalities - were assessed in order to select the recommended doses for a phase 2 study. RESULTS: At the data-cutoff date, 232 patients had received talquetamab (102 intravenously and 130 subcutaneously). At the two subcutaneous doses recommended for a phase 2 study (405 μg per kilogram weekly [30 patients] and 800 μg per kilogram every other week [44 patients]), common adverse events were cytokine release syndrome (in 77% and 80% of the patients, respectively), skin-related events (in 67% and 70%), and dysgeusia (in 63% and 57%); all but one cytokine release syndrome event were of grade 1 or 2. One dose-limiting toxic effect of grade 3 rash was reported in a patient who had received talquetamab at the 800-μg dose level. At median follow-ups of 11.7 months (in patients who had received talquetamab at the 405-μg dose level) and 4.2 months (in those who had received it at the 800-μg dose level), the percentages of patients with a response were 70% (95% confidence interval [CI], 51 to 85) and 64% (95% CI, 48 to 78), respectively. The median duration of response was 10.2 months and 7.8 months, respectively. CONCLUSIONS: Cytokine release syndrome, skin-related events, and dysgeusia were common with talquetamab treatment but were primarily low-grade. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma. (Funded by Janssen Research and Development; MonumenTAL-1 ClinicalTrials.gov number, NCT03399799.).
Overview
CoChat Summary
TL;DR
In the phase 1 MonumenTAL-1 study, talquetamab, a GPRC5D×CD3 bispecific antibody, produced substantial responses in heavily pretreated relapsed or refractory multiple myeloma at subcutaneous doses recommended for phase 2. Common adverse events were cytokine release syndrome, skin-related events, and dysgeusia, and these were primarily low-grade.
Key findings
- Among 232 treated patients (102 intravenous, 130 subcutaneous), the subcutaneous phase 2–recommended doses produced response rates of 70% (95% CI, 51 to 85) at 405 μg/kg weekly (n=30) and 64% (95% CI, 48 to 78) at 800 μg/kg every other week (n=44); median durations of response were 10.2 months and 7.8 months, respectively, at median follow-ups of 11.7 and 4.2 months.
- At the 405-μg and 800-μg subcutaneous doses, common adverse events were cytokine release syndrome (77% and 80%), skin-related events (67% and 70%), and dysgeusia (63% and 57%); all but one cytokine release syndrome event were grade 1 or 2.
- Among patients with triple-class-refractory disease, 65% at 405 μg and 70% at 800 μg had a response; among those with penta-drug-refractory disease, 83% and 78% had a response. Among 16 patients with previous exposure to BCMA-directed bispecific antibodies or CAR T-cell therapies, 8 (50%) had a response.
- Among 16 patients with samples available for minimal residual disease analysis who had a complete response or stringent complete response across all cohorts, 11 (69%) had no minimal residual disease at the 10⁻⁵ threshold.
Methods
- Ongoing phase 1, open-label, multicenter MonumenTAL-1 study (NCT03399799) with dose escalation (part 1) and dose expansion (part 2); eligible patients were ≥18 years old with measurable myeloma per IMWG criteria, disease progression with established therapies or inability to receive them without unacceptable side effects, ANC ≥1000 cells/mm³, platelets ≥50,000/mm³, and creatinine clearance ≥40 ml/min/1.73 m².
- Talquetamab was given intravenously weekly or every other week (0.5 to 180 μg/kg) or subcutaneously weekly, every other week, or monthly (5 to 1600 μg/kg), with step-up doses and pretreatment glucocorticoid, antihistamine, and acetaminophen. Primary end points were frequency and type of dose-limiting toxic effects (part 1 only), adverse events, and laboratory abnormalities; key secondary end points included response, pharmacokinetics, pharmacodynamics, and immunogenicity, with minimal residual disease as exploratory.
- Dose escalation used modified continual reassessment methods based on a Bayesian logistic-regression model with overdose control; safety was assessed in all treated patients, efficacy in those with at least one postbaseline disease assessment and evaluable response, and response was calculated as partial response or better with two-sided 95% confidence intervals using descriptive statistics.
Limitations
- The paper states limitations including small patient numbers at each dose level, differing follow-up between the subcutaneous phase 2–recommended doses because of different initiation times, and that this was a single-group study, so direct comparison with other agents was not possible; corroboration is under way in a phase 2 study.
- The paper notes that comparisons between studies may not control for important variables, and the text makes evident that this is an early, ongoing study with short median follow-up at the 800-μg dose level (4.2 months) and no randomized control group.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 94 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
What the sources say
- Not checked yetcites [13] 13. Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 2012; 42: 953-60. source
- Not checked yetcites [14] 14. Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020; 135: 1232-43. source
- Disputedcites [16] 16. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 2019; 11(485): eaau7746. sourceExperimental — accuracy not yet measured
Our copy supports the enrichment half (Results, 'Expression of GPRC5D by MM cells': GPRC5D mRNA high in MM cell lines and 1000-fold more in primary malignant plasma cells than B cells; Q-IF showing protein on CD138+ cells in 65% of 83 samples). But it directly contradicts the attributed association with high-risk markers: the same section reports that in the MMRF CoMMpass cohort (n=765) 'GPRC5D expression did not correlate with International Staging System score or any evaluated common cytogenetic abnormality (fig. S2, B and C).' The only prognostic association this paper reports is above-median GPRC5D expression with shorter progression-free survival (P = 0.0031), and even that is credited as confirming a prior 48-patient study (ref. 20, Atamaniuk et al. 2012), not as an association with high-risk disease markers. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [19] 19. Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific T cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther 2019; 18: 1555-64. source
- Supportedcites [20] 20. Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talqueta mab in multiple myeloma. Blood Adv 2021; 5: 2196-215. source
The 'GPRC5D gene expression' section (p. 5) reports that in 1421 MM patients from five prospective trials, significantly higher GPRC5D levels were observed in patients with t(4;14) and gain 1q — cytogenetic markers of high-risk myeloma (the paper's own Table 1, p. 4, lists t(4;14) among 'High-risk cytogenetics') — and significantly lower levels in standard-risk t(11;14). The enrichment half is stated in the flow-cytometry results (p. 3) and the Discussion (p. 13): MM cells express significantly higher GPRC5D mRNA and protein than normal plasma cells. Note the paper adds that GPRC5D was not associated with ISS, del(17p) or other abnormalities, and showed no prognostic association on Cox analysis, but the claim as worded ('associated with markers of high-risk myeloma') is what our copy states. (LLM, conf=0.85)
- Not checked yetcites [21] 21. Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology 2013; 18: 348-51. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Talquetamab (JNJ-64407564), a bispecific IgG4 antibody with a proline, alanine, alanine scaffold designed to minimize Fc-receptor binding, binds to both GPRC5D and CD3 to induce killing of GPRC5D-expressing myeloma cells by means of T-cell recruitment and activation. 14,20”
What the sources say
- Not checked yetcites [14] 14. Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020; 135: 1232-43. source
- Supportedcites [20] 20. Verkleij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talqueta mab in multiple myeloma. Blood Adv 2021; 5: 2196-215. source
The Discussion (p. 14) states exactly the mechanism the citation is offered for: talquetamab 'redirects T cells to MM cells by cross-linking the activating receptor CD3 on T cells and GPRC5D on the cell surface of the tumor cells,' with killing of GPRC5D+ MM cells followed by T-cell activation, cytokine secretion and degranulation. Results (p. 5) and Key Points (p. 2) corroborate dose-dependent lysis of GPRC5D+ MM lines/primary MM cells with T-cell activation and degranulation, and no lysis of GPRC5D-negative cells. The molecule-format descriptors in the citing sentence (JNJ-64407564, IgG4, proline-alanine-alanine scaffold, minimized Fc-receptor binding) do not appear in our copy, but they attach to the co-citation rather than to the mechanism clause this reference is offered for. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“with a response in 29.8% and median overall survival of 12.4 months. 8”
What the sources say
- Supportedcites [8] 8. Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, noninterventional, multinational study of reallife current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022; 36: 1371-6. source
The Results > Efficacy section (p. ~4) states exactly what the citing sentence attributes: 'The ORR for patients treated with real-life SOC therapy was 29.8% (95% CI: 24.2–36.0)' and 'Median PFS was 4.6 months ... and median OS was 12.4 months (95% CI: 10.28–NE)'. The Discussion repeats this framing for the cohort ('ORR (29.8%) was low, and median PFS (4.6 months) and median OS (12.4 months) were short'), and the study population is relapsed/refractory MM triple-class exposed to a PI, IMiD and anti-CD38 mAb, 73.8% of whom were triple-class refractory at baseline (subgroup median OS 11.1 months). The paraphrase's population wording is slightly looser than the paper's 'triple-class exposed RRMM', but the attributed figures and the standard-of-care setting match our copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients with triple-class-refractory multiple myeloma (i.e., disease that is refractory to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) or relapsed multiple myeloma who receive standard treatment have a poor prognosis, with a response in 29.8% and median overall survival of 12.4 months. 8”
What the sources say
- Supportedcites [8] 8. Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, noninterventional, multinational study of reallife current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022; 36: 1371-6. source
The Abstract (p. 1) and Discussion report exactly the attributed figures for the LocoMMotion cohort of relapsed/refractory patients exposed to a PI, IMiD and anti-CD38 mAb treated with real-life standard of care: ORR 29.8% (95% CI 24.2–36.0) and median OS 12.4 months (95% CI 10.3–NE), described as 'poor outcomes with currently available treatments' and 'rapid disease progression'. The Discussion (p. ~) notes 74% of the enrolled patients were triple-class refractory, an adverse prognostic factor (median PFS 3.9 vs 8.2 months; Results > Efficacy gives ORR 25.1% and median OS 11.1 months in that subgroup), so the quoted 29.8%/12.4-month values are the whole triple-class-exposed RRMM cohort rather than the refractory subset alone. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“with a response in 29.8% and median overall survival of 12.4 months. 8”
What the sources say
- Supportedcites [8] 8. Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, noninterventional, multinational study of reallife current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 2022; 36: 1371-6. source
The Efficacy section (p. Results) states 'The ORR for patients treated with real-life SOC therapy was 29.8% (95% CI: 24.2–36.0)... median OS was 12.4 months', and the Discussion repeats 'ORR (29.8%) was low, and median PFS (4.6 months) and median OS (12.4 months) were short'. This is exactly what the citing sentence attributes. The bounding population in LocoMMotion is relapsed/refractory MM patients who are triple-class EXPOSED (all 248 treated patients; 73.8% triple-class refractory at baseline), so the 29.8% figure covers the whole cohort rather than the refractory subgroup alone, whose ORR was 25.1% (Results, Efficacy). (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 3 with their cited sources checked
Create a free account to see all 107 claims and to verify the 18 references still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 11
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Clinical studies have demonstrated the percentages of RRMM patients who responded to talquetamab were 70% (95% CI, 51 to 85) and 64% (95% CI, 48 to 78) at doses of 800 µg and 405 µg per kilogram weekly, respectively. The median duration of response (mDOR) for patients treated with talquetamab at 800 µg and 405 µg per kilogram weekly was 10.2 months and 7.8 months, respectively [216, 217].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [217]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Talquetamab is another novel bispecific antibody that binds to G protein–coupled receptor class C group 5 member D (GPRC5D) on myeloma cells and CD3 on T cells.93”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“Although anti-BCMA therapies are approved and have shown clinical benefit for patients with relapsed or refractory multiple myeloma,4–7 relapses continue; thus, there is a need for novel therapies to expand treatment options.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [4]
Citations
Cites
The GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citation
Research works printed but not linked: 2
- Cornax I Yao X Ma JY Goldsmith RB Carreira V. Histology-guided in silico target expression analysis to support immunooncology therapeutic development. Presented at the 2021 Society of Toxicologic Pathology 40th Annual Symposium virtual June 28–30 2021. poster 25.
- 10.1002/(sici)1097-0258(19980530)17:10 · doi:10.1002/(sici)1097-0258(19980530)17:10
Cited by
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M., Chojnacka, M., Cirrincione, A., Durante, M., Tilmont, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02491-5 · Cited by 355
Self-citation
Metadata
- Authors
- Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., Verona, R., Girgis, S., Yang, S., Goldsmith, R. B., Yao, X., Pillarisetti, K., Hilder, B. W., Russell, J., Goldberg, J. D., & Krishnan, A.
- Affiliations
- Utrecht University (NL)
- From the Mount Sinai School of Medicine, New York (A.C.); University Medical Center Utrecht, Utrecht University, Utrecht (M.C.M.), and Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.) — both in the Netherlands; Sarah Cannon Research Institute and Tennessee Oncology, Nashville (J.G.B.); Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona (A.O.), Clínica Universidad de Navarra, Pamplona (P.R.-O.), Hospital Universitario Fundación Jiménez Díaz, Madrid (E.A.), and University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (M.-V.M.) — all in Spain; the University of Alabama at Birmingham, Birmingham (L.J.C.); Centre Hospitalier Universitaire de Liège, Liege, Belgium (J.C.); Janssen Research and Development, Spring House, PA (R.V., S.G., S.Y., R.B.G., K.P., B.W.H., J.R....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-15
- Volume
- 387
- Issue
- 24
- Pages
- 2232-2244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4312072518
- Semantic Scholar
- 6c400ad865b09203adfea18ca3e6213f60160aa8
- Cited by
- 744
- References
- 34
- Citations by year
- 2026: 201 · 2025: 227 · 2024: 198 · 2023: 114 · 2022: 1
- FWCI
- 98.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- talquetamab, GPRC5D, multiple myeloma, bispecific antibodies, T cell redirection, CD3, relapsed/refractory multiple myeloma, cytokine release syndrome, dose-limiting toxicity, subcutaneous administration, plasma cells, adverse events, rash, dysgeusia, response rate, progression-free survival
- MeSH terms
- Cytokine Release Syndrome, Dysgeusia, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Skin Diseases, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, Receptors, G-Protein-Coupled, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejmoa2204591
- The paper
- Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., Verona, R., Girgis, S., Yang, S., Goldsmith, R. B., Yao, X., Pillarisetti, K., Hilder, B. W., Russell, J., Goldberg, J. D., & Krishnan, A. (2022). Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2204591
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.